Nanobiotix Announces Temporary Trading Halt of Its Ordinary Shares on Euronext Paris

Rhea-AI Summary

Nanobiotix (NASDAQ:NBTX) requested a temporary halt of trading in its ordinary shares on Euronext Paris starting May 21, 2026, at 9:00 a.m. CEST.

The halt supports allocation confirmations and pricing for a previously announced Global Offering of ADSs, ordinary shares, and pre-funded warrants, with trading expected to resume around 3:30 p.m. Paris time.

AI-generated analysis. Not financial advice.

News Market Reaction – NBTX

-6.90%

13 alerts

-6.90% News Effect

+4.6% Peak Tracked

-5.1% Trough Tracked

-$155M Valuation Impact

$2.09B Market Cap

0.7x Rel. Volume

On the day this news was published, NBTX declined 6.90%, reflecting a notable negative market reaction. Argus tracked a peak move of +4.6% during that session. Argus tracked a trough of -5.1% from its starting point during tracking. Our momentum scanner triggered 13 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $155M from the company's valuation, bringing the market cap to $2.09B at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Trading halt date: May 21, 2026 Trading resume time Paris: 3:30 p.m. Trading resume time New York: 9:30 a.m. +2 more

5 metrics

Trading halt date May 21, 2026 Effective from Euronext Paris market opening

Trading resume time Paris 3:30 p.m. Expected Euronext Paris resumption on May 21, 2026

Trading resume time New York 9:30 a.m. Expected U.S. market resume time for Euronext Paris trading

Nominal value per share €0.03 Ordinary Share nominal value referenced in Global Offering

EU regulation reference Regulation (EU) 2017/1129 Article 2(e) Defines qualified investors for International Offering

Market Reality Check

Price: $35.46 Vol: Volume 92,855 is slightly...

normal vol

$35.46 Last Close

Volume Volume 92,855 is slightly below the 20-day average of 99,750 (relative volume 0.93). normal

Technical Shares at 43.16 are trading above the 200-day MA of 23.6, despite the pre-offering pullback.

Peers on Argus

NBTX fell 6.58% while key biotech peers like REPL (+5.52%) and ERAS (+7.13%) tra...

NBTX fell 6.58% while key biotech peers like REPL (+5.52%) and ERAS (+7.13%) traded higher, indicating a stock-specific move tied to the Global Offering and trading halt rather than a sector-wide decline.

Historical Context

5 past events · Latest: May 17 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
May 17	Phase 2 lung data	Positive	-3.9%	Early CONVERGE Part 1 lung cancer data with strong response rates.
May 04	Phase 3 protocol change	Positive	+11.6%	FDA-accepted NANORAY-312 amendment potentially accelerating final analysis timing.
Apr 20	Preclinical Nanoprimer data	Positive	-5.6%	New mouse data showing improved bioavailability and reduced toxicity with Nanoprimer.
Apr 07	Capital structure update	Neutral	+2.2%	Publication of shares outstanding and voting rights under transparency rules.
Mar 31	Full-year 2025 results	Positive	+10.4%	Report of €32.6M revenue, narrowed net loss and cash runway into early 2028.

Pattern Detected

Stock has shown mixed reactions, with sizable moves on clinical and financing-related updates and occasional selloffs on otherwise positive data.

Recent Company History

Over recent months, Nanobiotix has combined clinical progress with capital and disclosure actions. Positive full‑year 2025 results and business updates on Mar 31 coincided with a 10.37% gain, while protocol changes to the Phase 3 NANORAY‑312 trial on May 4 saw an 11.59% rise. Conversely, encouraging preclinical and early clinical data on Apr 20 and May 17 were followed by declines. The current trading halt and Global Offering follow this pattern of material financing and clinical catalysts.

Market Pulse Summary

The stock moved -6.9% in the session following this news. A negative reaction despite prior positive...

Analysis

The stock moved -6.9% in the session following this news. A negative reaction despite prior positive clinical updates fits a history where financing and data events have produced volatile swings, including declines of 5.56% and 3.92% after favorable announcements. The trading halt and Global Offering may have sharpened focus on dilution and capital needs. Such moves can reflect re-pricing of risk as new shares and warrants are placed, especially after a large run from the 52-week low.

Key Terms

american depositary shares, pre-funded warrants, qualified investors, regulation (eu) 2017/1129, +2 more

6 terms

american depositary shares financial

"a public offering of its American Depositary Shares (“ADSs”), each ADS representing"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

pre-funded warrants financial

"an offering of (a) its Ordinary Shares and (b) pre-funded warrants to subscribe for"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

qualified investors regulatory

"exclusively addressed to “qualified investors” in Europe (including France) within"

Qualified investors are individuals or institutions that meet regulatory standards—such as a minimum income, net worth, or professional expertise—allowing them access to investment opportunities not open to the general public. Think of them as a financial "VIP" group: they can buy private deals, complex products, or early-stage securities that may offer higher returns but also carry greater risk and less public information, so their status matters because it changes what investments are available and what protections apply.

regulation (eu) 2017/1129 regulatory

"within the meaning of Article 2(e) of Regulation (EU) 2017/1129, as amended"

An EU law that sets uniform rules for the detailed disclosure document companies must give when offering securities to the public or listing them on markets. It matters to investors because it forces issuers to present a clear, standardized “label” of information—risks, business model, finances and terms—so you can compare offerings and spot missing or misleading claims. Think of it as a required ingredient list and instructions for financial products sold across the EU.

global offering financial

"the “International Offering” and, together with the U.S. Offering, the “Global Offering”"

A global offering is when a company sells its shares or other securities to investors in multiple countries at the same time, combining new shares and sometimes existing ones. It matters to investors because it can change how many shares are available, affect the stock’s price and liquidity, and bring in capital or let insiders cash out—much like a concert releasing tickets worldwide at once, expanding the buyer pool and influencing demand and resale value.

trading halt technical

"trading of its ordinary shares on the regulated market of Euronext Paris ... will be temporarily halted"

A trading halt is a temporary pause on buying and selling a particular stock imposed by an exchange or regulator, like pressing the pause button on a game so everyone can catch up. It is used to give the market time to absorb important new information or to prevent chaotic price swings, and matters to investors because it freezes the ability to trade, delays price discovery, and can change risk and strategy until normal trading resumes.

AI-generated analysis. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PARIS and CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announces today that trading of its ordinary shares on the regulated market of Euronext Paris (“Euronext Paris”) will be temporarily halted, at the Company’s request, from the opening of the market at 9:00 a.m. CEST. This trading halt takes place in the context of the previously announced offering consisting of (i) a public offering of its American Depositary Shares (“ADSs”), each ADS representing one ordinary share, €0.03 nominal value per share (each an “Ordinary Share”), of the Company, in the United States (the “U.S. Offering”) and (ii) an offering of (a) its Ordinary Shares and (b) pre-funded warrants to subscribe for Ordinary Shares, exclusively addressed to “qualified investors” in Europe (including France) within the meaning of Article 2(e) of Regulation (EU) 2017/1129, as amended, and certain other countries (excluding the United States and Canada) (the “International Offering” and, together with the U.S. Offering, the “Global Offering”), in order to allow for the confirmation of allocations to investors and the announcement of the pricing of the Global Offering.

This suspension will be effective until a new communication is released by the Company. Trading on Euronext Paris is expected to resume on May 21, 2026, at approximately at approximately 3:30 p.m. (Paris time) / 9:30 a.m. (New York time).

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States), amongst other locations.

Nanobiotix is the owner of more than 25 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

Contacts

Nanobiotix
Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com	Investor Relations Department Joanne Choi VP, Investor Relations (US) +1 (713) 609-3150 Ricky Bhajun Director, Investor Relations (EU) investors@nanobiotix.com
Media Relations
France – HARDY Caroline Hardy + 33 06 70 33 49 50 carolinehardy@outlook.fr		Global – uncapped Communications Becky Lauer +1 (646) 286-0057 uncappednanobiotix@uncappedcommunications.com

Disclaimers

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities of the Company, nor shall there be any sale of such securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Attachment

• 2026-05-21 -- NBTX -- Trading Halt -- FINAL

FAQ

Why was Nanobiotix (NASDAQ:NBTX) trading halted on Euronext Paris on May 21, 2026?

Trading in Nanobiotix ordinary shares on Euronext Paris was halted at the company’s request. According to Nanobiotix, the halt supports confirming investor allocations and announcing pricing for its previously announced Global Offering in the United States and Europe.

When will Nanobiotix (NBTX) trading resume on Euronext Paris after the May 21, 2026 halt?

Nanobiotix expects trading in its ordinary shares on Euronext Paris to resume May 21, 2026. According to Nanobiotix, the planned restart time is approximately 3:30 p.m. Paris time, corresponding to about 9:30 a.m. in New York.

What is the Global Offering mentioned in Nanobiotix (NBTX) May 21, 2026 trading halt announcement?

The Global Offering combines a U.S. public ADS offering with an international offering of ordinary shares and pre-funded warrants. According to Nanobiotix, the international tranche targets qualified investors in Europe and certain other countries, excluding the United States and Canada.

How are Nanobiotix (NBTX) ADSs and ordinary shares involved in the May 2026 Global Offering?

The Global Offering includes American Depositary Shares in the United States and ordinary shares plus pre-funded warrants internationally. According to Nanobiotix, each ADS represents one ordinary share with a nominal value of €0.03 per share.

Is the Nanobiotix (NBTX) trading halt on Euronext Paris related to pricing of its Global Offering?

Yes, the trading suspension is directly connected to the Global Offering process. According to Nanobiotix, the halt allows time to confirm investor allocations and to announce the final pricing terms for the combined U.S. and international offerings.